43742-2142 NDC - ENT SUPPORT (ARGENTUM NITRICUM, ASPERGILLUS NIGER, CANDIDA ALBICANS, EUPHORBIUM OFFICINARUM, GALLICUM ACIDUM, HEPAR SULPHURIS CALCAREUM, INFLUENZINUM (2023-2024), LUFFA OPERCULATA, MERCURIUS IODATUS RUBER, MUCOR RACEMOSUS, MUTABILE BACILLUS (BACH), PULSATILLA (PRATENSIS), SINUSITISINUM)

Drug Information

Product NDC: 43742-2142
Proprietary Name: ENT Support
Non Proprietary Name: Argentum Nitricum, Aspergillus Niger, Candida Albicans, Euphorbium Officinarum, Gallicum Acidum, Hepar Sulphuris Calcareum, Influenzinum (2023-2024), Luffa Operculata, Mercurius Iodatus Ruber, Mucor Racemosus, Mutabile Bacillus (Bach), Pulsatilla (Pratensis), Sinusitisinum
Active Ingredient(s): 10 [hp_C]/mL ASPERGILLUS NIGER VAR. NIGER; 10 [hp_X]/mL CALCIUM SULFIDE; 10 [hp_C]/mL CANDIDA ALBICANS; 30 [hp_C]/mL ESCHERICHIA COLI; 6 [hp_X]/mL EUPHORBIA RESINIFERA RESIN; 10 [hp_C]/mL GALLIC ACID MONOHYDRATE; 12 [hp_C]/mL INFLUENZA A VIRUS A/DARWIN/6/2021 (H3N2) WHOLE; 12 [hp_C]/mL INFLUENZA A VIRUS WHOLE; 12 [hp_C]/mL INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 WHOLE; 12 [hp_C]/mL INFLUENZA B VIRUS B/PHUKET/3073/2013 BVR-1B WHOLE; 6 [hp_X]/mL LUFFA OPERCULATA FRUIT; 8 [hp_X]/mL MERCURIC IODIDE; 10 [hp_C]/mL MUCOR RACEMOSUS; 4 [hp_X]/mL PULSATILLA PRATENSIS WHOLE; 10 [hp_X]/mL SILVER NITRATE; 17 [hp_X]/mL SINUSITISINUM
Administration Route(s): ORAL
Dosage Form(s): LIQUID
Pharmacy Class(es): Allergens [CS]; Allergens [CS]; Allergens [CS]; Cell-mediated Immunity [PE]; Cell-mediated Immunity [PE]; Cell-mediated Immunity [PE]; Fungal Proteins [CS]; Fungal Proteins [CS]; Fungal Proteins [CS]; Increased Histamine Release [PE]; Increased Histamine Release [PE]; Increased Histamine Release [PE]; Increased IgG Production [PE]; Increased IgG Production [PE]; Increased IgG Production [PE]; Non-Standardized Fungal Allergenic Extract [EPC]; Non-Standardized Fungal Allergenic Extract [EPC]; Non-Standardized Fungal Allergenic Extract [EPC]

Labeler Information

Field Name	Field Value
Labeler Name:	Deseret Biologicals, Inc.
Product Type:	HUMAN OTC DRUG
FDA Application Number:
Marketing Category:	UNAPPROVED HOMEOPATHIC
Start Marketing Date:	3/13/2024
End Marketing Date:	5/17/2029

Package Information

No.	Package Code	Package Description	Billing Unit
1	43742-2142-1	30 mL in 1 BOTTLE, DROPPER (43742-2142-1)

NDC Record

Field Name	Field Value	Definition
PRODUCT NDC	43742-2142	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAME	HUMAN OTC DRUG	Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAME	ENT Support	The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAME	Argentum Nitricum, Aspergillus Niger, Candida Albicans, Euphorbium Officinarum, Gallicum Acidum, Hepar Sulphuris Calcareum, Influenzinum (2023-2024), Luffa Operculata, Mercurius Iodatus Ruber, Mucor Racemosus, Mutabile Bacillus (Bach), Pulsatilla (Pratensis), Sinusitisinum	The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAME	LIQUID	The translation of the dosage form Code submitted by the firm.
ROUTE NAME	ORAL	The translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE	3/13/2024	This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE	5/17/2029	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAME	UNAPPROVED HOMEOPATHIC	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAME	Deseret Biologicals, Inc.	Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAME	ASPERGILLUS NIGER VAR. NIGER; CALCIUM SULFIDE; CANDIDA ALBICANS; ESCHERICHIA COLI; EUPHORBIA RESINIFERA RESIN; GALLIC ACID MONOHYDRATE; INFLUENZA A VIRUS A/DARWIN/6/2021 (H3N2) WHOLE; INFLUENZA A VIRUS WHOLE; INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 WHOLE; INFLUENZA B VIRUS B/PHUKET/3073/2013 BVR-1B WHOLE; LUFFA OPERCULATA FRUIT; MERCURIC IODIDE; MUCOR RACEMOSUS; PULSATILLA PRATENSIS WHOLE; SILVER NITRATE; SINUSITISINUM	An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH	10; 10; 10; 30; 6; 10; 12; 12; 12; 12; 6; 8; 10; 4; 10; 17
ACTIVE INGRED UNIT	[hp_C]/mL; [hp_X]/mL; [hp_C]/mL; [hp_C]/mL; [hp_X]/mL; [hp_C]/mL; [hp_C]/mL; [hp_C]/mL; [hp_C]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL
PHARM CLASSES	Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Fungal Proteins [CS], Fungal Proteins [CS], Fungal Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Increased IgG Production [PE], Increased IgG Production [PE], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC]

Drug Information

Labeler Information

Package Information

NDC Record

Download Record